COVID-19 therapeutics: Challenges and directions for the future
PC Robinson, DFL Liew, HL Tanner… - Proceedings of the …, 2022 - National Acad Sciences
The emergence of SARS-CoV-2 triggering the COVID-19 pandemic ranks as arguably the
greatest medical emergency of the last century. COVID-19 has highlighted health disparities …
greatest medical emergency of the last century. COVID-19 has highlighted health disparities …
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations
The COVID-19 pandemic has brought challenges for people with rheumatic disease in
addition to those faced by the general population, including concerns about higher risks of …
addition to those faced by the general population, including concerns about higher risks of …
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the …
Background The risk of severe COVID-19 outcomes in people with immune-mediated
inflammatory diseases and on immune-modifying drugs might not be fully mediated by …
inflammatory diseases and on immune-modifying drugs might not be fully mediated by …
Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019
Background The causes for immune-mediated inflammatory diseases (IMIDs) are diverse
and the incidence trends of IMIDs from specific causes are rarely studied. The study aims to …
and the incidence trends of IMIDs from specific causes are rarely studied. The study aims to …
Prospective roles of tumor necrosis factor-alpha (TNF-α) in COVID-19: prognosis, therapeutic and management
Z Mohd Zawawi, J Kalyanasundram… - International journal of …, 2023 - mdpi.com
The coronavirus disease 2019 (COVID-19) became a worldwide concern at the beginning of
2020 and has affected millions. Several previous studies revealed the impact of the …
2020 and has affected millions. Several previous studies revealed the impact of the …
COVID‐19 immunopathology: from acute diseases to chronic sequelae
The clinical manifestation of coronavirus disease 2019 (COVID‐19) mainly targets the lung
as a primary affected organ, which is also a critical site of immune cell activation by severe …
as a primary affected organ, which is also a critical site of immune cell activation by severe …
SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider …
Objective While COVID-19 vaccination prevents severe infections, poor immunogenicity in
immunocompromised people threatens vaccine effectiveness. We analysed the clinical …
immunocompromised people threatens vaccine effectiveness. We analysed the clinical …
Safety of Janus kinase inhibitors in inflammatory bowel diseases
P Núñez, R Quera, AJ Yarur - Drugs, 2023 - Springer
In recent years, better knowledge of the pathophysiology of inflammatory bowel diseases
(IBD) has led to a relevant expansion of the therapeutic arsenal for these conditions. Janus …
(IBD) has led to a relevant expansion of the therapeutic arsenal for these conditions. Janus …
Novel insights into the management of rheumatoid arthritis: one year in review 2022
C Garaffoni, A Adinolfi, A Bortoluzzi… - Clinical and …, 2022 - sfera.unife.it
New evidence for the treatment of rheumatoid arthritis (RA) has emerged during the last
year. Specifically, updated guidelines on pharmacological and non-pharmacological …
year. Specifically, updated guidelines on pharmacological and non-pharmacological …
The T-cell response to SARS-CoV-2 vaccination in inflammatory bowel disease is augmented with anti-TNF therapy
Lay Summary T-cell and antibody responses to severe acute respiratory syndrome
coronavirus 2 vaccination in inflammatory bowel disease patients are poorly correlated. T …
coronavirus 2 vaccination in inflammatory bowel disease patients are poorly correlated. T …